The JAK/STAT6 pathway may, thus, further contribute to UGT2B17 oncogenic functions, and our results imply that it could constitute a therapeutic vulnerability in UGT2B17HI CLL cases. This evidence concerns the gene UGT2B17 and B-cell chronic lymphocytic leukemia.